The Heart Protection Study: Implications for clinical practice: The benefits of statin therapy do not come without financial cost

Medical Journal of Australia

Volumn 177, Issue 8, 2002, Pages 407-408

  Hamilton Craig, Ian ^a  

^a North Adelaide Cardiac Clinic   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CHOLESTEROL; CREATINE KINASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

AGE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COST CONTROL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; EDITORIAL; HEALTH CARE AVAILABILITY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LONG TERM CARE; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOPATHY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SMOKING CESSATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

EID: 0037152928     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2002.tb04877.x     Document Type: Editorial

References (11)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
3. Yusuf S. Two decades of preventing vascular disease. Lancet 2002; 360: 2-3.
4. National Prescribing Service. Dyslipidaemia - background material. Sydney: National Prescribing Service Limited, 2002.
5. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
7. Saltissi D, Morgan C, Rigby RJ, Westhuysen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39: 369-375.
8. Masterson TM. Safety and efficacy of simvastatin in patients undergoing chronic renal dialysis: are we ready to treat hypercholesterolemia? Am J Kidney Dis 2002; 39: 419-421.
9. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175: 486-489.
10. Iso H, Jacobs DR Jr, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-910.
11. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000; 132: 769-779.